Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2007
06/14/2007US20070135434 Sulfonyloxy derivatives
06/14/2007US20070135433 Imidazole derivatives as raf kinase inhibitors
06/14/2007US20070135432 Mitotic kinesin KSP inhibitors; antiproliferative agents; 2-methylpyrimidin-4-ones
06/14/2007US20070135431 Inhibitors of histone deacetylase for the treatment of disease
06/14/2007US20070135430 Administering a 1-(2-aminoalkyl)-1H-furo(2,3-g)indazole, e.g.,N-(3-hydroxy-2,2-dimethylpropyl)-1-((S)-2-aminopropyl)-1H-furo[2,3-g]indazole-7-carboxamide; serotonin receptor agonists
06/14/2007US20070135429 10,11-dimethoxydibenzo[c,f]-2,7-naphthyridin-6-amine; inhibiting pyruvate dehydrogenase kinase PDK-1in a cell; antiproliferative agent;brain, colon cancer, leukemia, prostate and breast cancer
06/14/2007US20070135428 Lactam containing cyclic diamines and derivatives as factor xa inhibitors
06/14/2007US20070135427 Glucocorticoid receptor modulators as antiinflammatory agents
06/14/2007US20070135426 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1(2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; thromboembolic disorder like deep vein thrombosis or pulmonary embolism; pyrazolo[3,4-c]pyridine derivatives; blood coagulation factor (trypsin-like serine protease enzymes) inhibitors
06/14/2007US20070135425 pyrido[4,3-b]carbazol derivatives; melanin-concentrating hormone (MCH) and somatostatin receptors modulator; eating disorders; obesity; anxiolytic agents; psychological disorders
06/14/2007US20070135424 Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase
06/14/2007US20070135423 E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain
06/14/2007US20070135422 Nitrogen-containing bicycle heterocycles for use as antibacterials
06/14/2007US20070135421 e.g. Methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate; GABAA (gamma aminobutiric acid) receptor antagonist; sedative-hypnotic, anxiolytic, muscle relaxant and anticonvulsant; anesthesia
06/14/2007US20070135420 Short-acting benzodiazepines
06/14/2007US20070135419 Short-acting benzodiazepines
06/14/2007US20070135418 Compositions and methods relating to novel compounds and targets thereof
06/14/2007US20070135417 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles,and chromones and preparation and uses thereof
06/14/2007US20070135416 Tricyclic amide derivatives
06/14/2007US20070135415 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
06/14/2007US20070135414 Tachykinin Antagonists
06/14/2007US20070135413 Treatment of glial tumors with glutamate antagonists
06/14/2007US20070135412 Compounds for the treatment of ocular dryness caused by photorefractive surgery
06/14/2007US20070135411 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
06/14/2007US20070135410 3-Aminopyrrolidone derivatives
06/14/2007US20070135409 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
06/14/2007US20070135407 Serm reduction of lipid profiles
06/14/2007US20070135406 Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain
06/14/2007US20070135405 Novel diazabicyclononene and tetrahydropyridine derivatives with a new polar side-chain
06/14/2007US20070135404 e.g. N-[1-(2-aminoethyl)-4-piperidinyl]-7-methyl-3-(8-quinolinylmethyl)-3H-imidazo[4,5-b]pyridin-2-amine tetrahydrochloride trihydrate; immunostimulant; lower respiratory tract illness during infancy and childhood, asthma, pneumonia
06/14/2007US20070135403 Substituted 2,5-diaminomethyl-1H-pyrrole compounds
06/14/2007US20070135402 Azetidine ring compounds and drugs comprising the same
06/14/2007US20070135401 Lestaurtinib Crystalline Form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib
06/14/2007US20070135400 Estradiol derivatives
06/14/2007US20070135399 Heteroaromatic sulphonamide prodrugs
06/14/2007US20070135398 Process for the preparation of ciclesonide
06/14/2007US20070135397 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations
06/14/2007US20070135396 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations
06/14/2007US20070135395 Novel method for the preparation of intermediates useful for the synthesis fo vitamin d analogues
06/14/2007US20070135394 Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds
06/14/2007US20070135393 Prevention of deficits in neurogenesis with anti-inflammatory agents
06/14/2007US20070135392 Apoptosis promoters
06/14/2007US20070135390 Phosphate derivatives
06/14/2007US20070135389 calcium and sodium mixed salt of inositol tripyrophosphate; anticancer
06/14/2007US20070135388 Novel Bicyclic Cannabinoids
06/14/2007US20070135387 Inhibitors of protein kinases
06/14/2007US20070135386 Novel Compounds and Compositions as Cathepsin Inhibitors
06/14/2007US20070135385 Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction
06/14/2007US20070135384 Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
06/14/2007US20070135383 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
06/14/2007US20070135382 Use of peroxisome proliferator-activated receptor gamma (ppary) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions
06/14/2007US20070135381 Derivatives of branch-chain lipophilic molecular and uses thereof
06/14/2007US20070135380 O-nitro compounds, pharmaceutical compositions thereof and uses thereof
06/14/2007US20070135379 Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle
06/14/2007US20070135378 Method for the direct synthesis of oligorhamnosides, composition comprising oligorhamnosides and use thereof as a medicament
06/14/2007US20070135377 Thixotropic anti-viral formulation
06/14/2007US20070135376 Method to reduce oxidative damage and improve mitochondrial efficiency
06/14/2007US20070135375 Sulfamoyl sulfonate prodrugs
06/14/2007US20070135374 Composition for promoting collagen production
06/14/2007US20070135371 Antisense IAP nucleobase oligomers and uses thereof
06/14/2007US20070135367 Method for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity
06/14/2007US20070135365 Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby
06/14/2007US20070135363 For therapy of infectious diseases and proliferative disorders, such as viral infections or cancer
06/14/2007US20070135362 Method for demethylating the 3'-dimethylamino group of erythromycin compounds
06/14/2007US20070135361 Method of diagnosing alzheimer's disease by detection of chlamydia pneumoniae
06/14/2007US20070135360 Determining whether cerebralspinal fluid sample contains Chlamydia pneumoniae
06/14/2007US20070135359 Identification of Free-B-Ring Flavonoids as Potent COX-2 Inhibitors
06/14/2007US20070135358 Steroid modified solatrioses
06/14/2007US20070135357 Anti-hypercholesterolemic compounds
06/14/2007US20070135355 Functionalized diphenolics and absorbable polymers therefrom
06/14/2007US20070135354 Hematopoietic stimulation
06/14/2007US20070135353 Crystalline n-formyl hydroxylamine compounds
06/14/2007US20070135348 Methods and compositions for the treatment of peripheral artery disease
06/14/2007US20070135346 Prodrugs of CC-1065 analogs
06/14/2007US20070135345 Use of GLP-2 for the treatment or prevention, of bone-related disorders
06/14/2007US20070134763 Anti-virus therapy for respiratory diseases
06/14/2007US20070134758 Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors
06/14/2007US20070134744 Epothilone resistant cell lines
06/14/2007US20070134735 Transcriptional regulation of the human beta3-adrenergic receptor gene
06/14/2007US20070134729 Novel antibacterial agents
06/14/2007US20070134719 Method of controlling pharmacokinetics of immunomodulatory compounds
06/14/2007US20070134709 Usages of MTHFR gene polymorphisms in predicting homocysteine level, disease risk, and treatment effects and related methods and kit
06/14/2007US20070134688 Calculated index of genomic expression of estrogen receptor (er) and er-related genes
06/14/2007US20070134664 Human autism susceptibility gene and uses thereof
06/14/2007US20070134660 Methods for identifying modulators of kinesin activity
06/14/2007US20070134653 drug screening using virion infectivity factor (VIF) activity as diagnostic tool in screening viricidal activity of compounds; for treating viral diseases
06/14/2007US20070134646 Hyaluronic acid oligosaccharide fractions and drugs containing the same
06/14/2007US20070134355 Use of plant parts of prickly pear (opuntia) and/or extracts therefrom for the treatment of depressions
06/14/2007US20070134353 Phytoestrogenic composition comprising an extract of chinese licorice root, isoliquiritin or liquiritin
06/14/2007US20070134349 Methods of treating hematological malignancies
06/14/2007US20070134348 for an extracorporeal blood treatment; aqueous substitution infusion fluid comprising electrolytes but excluding magnesium and calcium, and infusion fluid comprising calcium ions and magnesium ions
06/14/2007US20070134342 Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins
06/14/2007US20070134341 Compositions of lipoxygenase inhibitors
06/14/2007US20070134340 Method for delivering hydrophobic drugs via nanocrystal formulations
06/14/2007US20070134339 Zonisamide and nsaid nanoparticulate formulations
06/14/2007US20070134335 Polypeptides with the capacity to entrap drugs and release them in a controlled way
06/14/2007US20070134331 Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine
06/14/2007US20070134330 Methods and compositions for improved image quality
06/14/2007US20070134329 Multi-particulate oral dosage form
06/14/2007US20070134328 Oxymorphone controlled release formulations
1 ... 3712 3713 3714 3715 3716 3717 3718 3719 3720 3721 3722 3723 3724 3725 3726 3727 3728 3729 3730 3731 3732 ... 7860